Promotie Rachel Kalf ‘Improving patient access to valuable new pharmaceuticals’

Opties

Rachel Kalf will defend her thesis ‘Improving patient access to valuable new pharmaceuticals’ on Monday April 15 at 2.15pm.You are welcome to witness her defense.

  • Datum 15 april 2024
  • Locatie Academiegebouw, Domplein 29, Utrecht
  • Start & eind tijd 14:15 - 15:15

In her thesis, Rachel described her contribution to the development of an evidence ecosystem to evaluate pharmaceuticals throughout their lifecycle. She assessed the role of outcomes that are measured throughout the healthcare process and showed that there is overlap in the outcomes used for market approval and reimbursement assessments of pharmaceuticals, as well as in a more general sense for determining the quality of care. These outcomes also appear to be patient relevant, as they are included in the standard sets of the International Consortium for Health Outcomes Measurement (ICHOM). In the second part of the thesis. Rachel focused on how to assess health related quality of life (HRQoL) in patients and in particular on how social media could be a potential source to quickly provide information on the HRQoL. She demonstrated that it can be used to listen to what patients are discussing online, but also to distribute questionnaires. Due to possible selection and information bias, social media is best used complementary to traditional research.

The research is the result of a collaboration between the Division of Pharmacoepidemiology and Clinical Pharmacology of the Utrecht Institute for Pharmaceutical Sciences (UIPS) of Utrecht University and National Health Care Institute, Diemen, The Netherlands and was partly funded through IMI GetReal projects. 

You can attend the defense online via https://video.uu.nl/lives/senate_hall_phd_defense_2023_2024/

The supervisory team

Prof. dr. ir. W.G. Goettsch (promotor), prof. dr. D.M.J. Delnoij (promotor), prof. dr. M.L. Bouvy (promotor)

Pagina laatst bijgewerkt op 27 maart 2024